Overview

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators will examine efficacy and toxicity of gefitinib in Korean patients with EGFR wild tumors diagnosed with direct sequence test.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Gefitinib